Radical’s 8-F Neurovascular Guide Catheter Evaluated in Initial Clinical Procedures

July 10, 2025—Radical Catheter Technologies, a NeuroTechnology Investors portfolio company, announced the initial clinical procedures with the 8-F Radical neurovascular guide catheter. In January 2025, the company announced FDA 510(k) clearance for the device, which is built on the same platform as Radical’s FDA-cleared 7-F catheter.

According to the company, 10 complex cases were conducted with the 8-F device at Mount Sinai Health Systems in New York, New York, and validate the flexibility, stability, and support of Radical’s next-generation ribbon technology.

Shahram Majidi, MD, Associate Professor of Neurosurgery at Icahn School of Medicine at Mount Sinai and codirector of the Neuroendovascular Surgery Fellowship at Mount Sinai Health System, performed the first procedures to evaluate the 8-F Radical catheter in a clinical setting.

“The 8-F catheter has exceeded my expectations and stands out as a best-in-class large-bore guide catheter,” commented Dr. Majidi in the company’s press release. “In these initial cases, the catheter demonstrated excellent trackability and navigated with ease to the distal intracranial segment of the internal carotid artery.

“It performed exceptionally well even through extremely tortuous anatomy, including a full 360º turn, without inducing vasospasm or dissection—complications that are not uncommon in such scenarios. Notably, there was no evidence of kinking or structural damage to the catheter at the end of the procedure, underscoring its durability.

"The 8-F Radical catheter provided remarkable stability and support, eliminating the need for an intermediate catheter to deliver our most complex treatment devices.”